On Wednesday, GE HealthCare (NYSE:GEHC) reported third-quarter 2025 adjusted earnings of $1.07 per share, which beat the consensus of $1.05.GEHC is having a challenging session. Watch the momentum hereIt was down from $1.14 a year ago due to the impact of tariff expenses.The company reported sales of $5.14 billion, beating the consensus of $5.08 billion.Revenues increased 6% on reported and 4% on an organic basis year-over-year. Revenue growth was driven by strength in the U.S. and the European, Middle East ...

3Q 2025 Earnings Presentation October 29, 2025 © 2025 GE HealthCare. GE is a trademark of General Electric Company used under trademark license. Forward-looking statements and additional information This presentation contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as "will," "expect," "may," "would," "could," "plan," "believe," "anticipate," "intend," "estimate," "potential," "position," "forecast," "target," "guidance," "outl ...

Accessibility StatementSkip Navigation OSLO, Norway, Oct. 29, 2025 /PRNewswire/ --Â Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 134.1 million in the third quarter of 2025 (Q3 2024: NOK 120.1 million), and an EBITDA of NOK 10.2 million (Q3 2024: NOK 5.0 million) for the company. Looking ahead, Photocure expects product revenue growth in the range of 8% to 10% on a constant currency basis (compared to 7 to 11% previously) and an EBITDA improvement in 2025. While the company is not ...

核心观点 - 美国医疗保险和医疗补助服务中心（CMS）发布了关于肾脏去神经术（RDN）的最终国家覆盖决定（NCD），适用于美敦力公司的Symplicity Spyral RDN系统，这将使符合条件的Medicare患者能够获得该疗法，用于治疗未受控制的高血压[1] 医保覆盖与市场准入 - 最终的国家覆盖决定为Medicare患者提供了使用Symplicity血压治疗程序的机会，以治疗未受控制的高血压[1] - 该决定为美敦力开辟了一个新颖且重要的市场，将其肾脏去神经技术定位为公司最令人兴奋的增长动力之一[1] - Symplicity Spyral系统已在美国主要中心提供，包括大型综合医疗网络，作为其高血压护理服务的一部分[1] 产品技术与临床数据 - Symplicity Spyral RDN系统是一种创新的微创手术，通过向肾脏附近可能过度活跃并导致高血压的神经输送射频能量来发挥作用[1] - 该系统于2023年11月获得美国食品药品监督管理局（FDA）批准[1] - 美敦力SPYRAL HTN全球临床项目是最全面的RDN临床研究项目，涉及超过5,000名患者，并得到全球超过30,000名患者经验的支持[3] - Symplicity Spyral RDN系统在随机对照和真实世界登记试验中已证明可持续降压长达三年[3] - Symplicity Spyral是唯一具有广泛、持久、一致、长期数据和单一导管设计的商用RDN设备[3] 高血压疾病负担 - 高血压是一种全球健康危机，是心脏病发作、中风和死亡的主要可改变原因[2] - 尽管有药物和生活方式改变等可用治疗方法，但许多患者的血压仍未得到控制，近80%的高血压成人患者病情未受控制，50%的高血压患者在一年内变得不坚持服药[2] 公司战略与影响 - 这一里程碑使医生在管理高血压时能为患者提供更多选择，可能为急需新选择的人群带来更好的结果[1] - 公司的商业团队将积极利用这一里程碑，与医疗保健提供者和高血压中心密切合作，以加速这一变革性增长机会的采用[1] - Symplicity Spyral RDN系统已在全球近80个国家获准商用[2]

A live webcast of the call will also be available from the Investor Relations section of the company's website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available until Accuray announces its results for the second quarter of fiscal 2026. About AccurayAccuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the ...

Accessibility StatementSkip Navigation PRINCETON, N.J., Oct. 28, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, honors the life and legacy of Dr. Robert Hawes Bartlett, MD (1939-2025), the company's former Chief Medical Officer from 2008-2017, who passed away last week at age 86. Dr. Robert Hawes Bartlett, MD - University of Michigan. Father of Extracorporeal Memb ...

SAN JOSE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the third quarter 2025 after the close of trading on Monday, November 10, 2025. On the same day, at 1:30 p.m. Pacific time (4:30 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Office ...

季度业绩表现 - 每股收益为1.18美元，超出Zacks共识预期1.14美元，带来3.51%的盈利惊喜，但低于去年同期1.28美元 [1] - 季度营收约为6.99亿美元，未达到7.62亿美元的预期，但高于去年同期的6.8405亿美元 [2] - 在过去四个季度中，公司持续超出共识每股收益预期，展现出有效的盈利预期管理能力 [2] 业务运营与展望 - 公司在竞争激烈的Zacks医疗服务行业中运营，并在过去四个季度中两次超出共识营收预期 [3] - 诊断部门检测试剂盒需求激增，推动公司上调了年度利润预测 [3] - 诊断领域的强劲表现为公司的积极前景做出贡献 [3] 关键财务比率与估值 - 市盈率约为40.69倍，显示投资者对其盈利潜力的信心 [4] - 市销率约为4.10倍，企业价值与销售额比率约为4.95倍，反映了市场对其营收的估值水平 [4] - 债务与权益比率约为0.45，表明债务水平相对于权益处于适度水平 [5] 财务健康状况 - 流动比率约为3.33，表明公司拥有强大的流动性，能够覆盖短期负债 [5] - 企业价值与营运现金流比率约为23.71，市场对其现金流给予积极估值 [5] - 收益率为约2.46%，为投资者提供了投资回报视角 [5]

文章核心观点 - 文章于10月27日推荐了三只具有买入评级和强劲动能特征的股票，分别为Perimeter Solutions、通用汽车和直觉外科 [1] Perimeter Solutions, SA (PRM) - 公司是消防产品和润滑剂添加剂制造商，获得Zacks Rank 1（强力买入）评级 [1] - 在过去60天内，公司当前年度盈利的Zacks共识预期上调了10.9% [1] - 公司股价在过去三个月上涨33.4%，同期标普500指数上涨6.4% [2] - 公司动能得分为A [2] 通用汽车 (GM) - 公司是全球最大汽车制造商之一，获得Zacks Rank 1（强力买入）评级 [2] - 在过去60天内，公司当前年度盈利的Zacks共识预期上调了7% [2] - 公司股价在过去三个月上涨30.7%，同期标普500指数上涨6.4% [2] - 公司动能得分为A [2] 直觉外科 (ISRG) - 公司设计、制造和销售达芬奇手术系统、Ion腔内系统及相关器械和配件，获得Zacks Rank 1（强力买入）评级 [3] - 在过去60天内，公司当前年度盈利的Zacks共识预期上调了5.5% [3] - 公司股价在过去三个月上涨10.7%，同期标普500指数上涨6.4% [4] - 公司动能得分为B [4]

Accessibility StatementSkip Navigation ALAMEDA, Calif., Oct. 27, 2025 /PRNewswire/ --Â Penumbra, Inc. (NYSE: PEN) announced the results of the landmark STORM-PE randomized controlled trial (RCT), which found that the use of mechanical thrombectomy, specifically computer assisted vacuum thrombectomy (CAVTâ"¢), with anticoagulation achieved superior reduction in right heart strain compared to nticoagulation therapy alone in patients with acute intermediate-high risk pulmonary embolism (PE). The data was prese ...